AIxCrypto Holdings, Inc. (AIXC) stock profile

Frequently asked questions

What does AIxCrypto Holdings, Inc. (AIXC) do?

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS, which is in the preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.

Where is AIXC stock listed?

AIxCrypto Holdings, Inc. trades under the ticker AIXC on NASDAQ.

How can I research AIXC's financials and filings?

Vantafin provides AIxCrypto Holdings, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the AIXC profile.